Suvir Singh

AI can certainly help with the mundane and clerical tasks. Yes. Thanks. AI is great at diagnosis. But diagnostic puzzles form a small portion of the care we give or the patients we see. Most of the time the diagnosis is obvious and the main decision is management based on the patients’ unique clinical features, their wishes, goals in life, and analysis of pros and cons based on other comorbidities. Standard best treatments apply to standard people. But patients are not standard. They are each a unique person and it takes judgment to make the right call on management.

@volklub Can I contact you regarding advise on some issues with Vento that started after service in Ludhiana?

Happy to share our paper on BCR/ABL Negative MPNs: •Mutational architecture influences survival in Indian MPN patients •Double-hit mutations confer nearly five-fold higher mortality risk •JAK2 with high-risk co-mutations defines a poor-risk subgroup doi.org/10.1016/j.leuk…

Designed for world wide. The high beta 2 applies only if normal renal function. So we wanted to keep it simple. Otherwise the risk Strat will also change by day if creat wobbles around a number. Just make a judgment call whether for the purposes of beta w is the renal function normal.

The website also allows you to calculate the new revised IMS IMWG risk stratification of myeloma.

Happy to share our paper on potential use of dynamic biomarkers (FLC and Creatinine) in identifying a high risk subset of pts with high light chain myeloma. doi.org/10.1007/s12288…

This is an incredible progress story An aggressive type of cancer (Philadelphia chromosome–positive acute lymphoblastic leukemia) used to carry a dismal prognosis, with 50% of patients dying in a year New therapies have transformed it to a cancer that most people are cured of

@AaronGoodman33 @DrDiGiorgio Completing six years of this solo!

No, doctors work without sleep because emergencies happen in the middle of the night and because frequent handoffs lead to things getting missed.

Received a challan for ‘jumping’ a red light when the traffic lights were off and some corner lights were blocked by a parked truck. @LudhianaTraffic @Ludhiana_Police

@marklewismd Insight 👍🏼

Taught my daughter’s science class about the thymus: how it looks huge at first & then “shrinks” But it’s a perspective trick because we actually grow around it Finally it really does regress but never quite vanishes Later: “Dad, the thymus is a metaphor for grief, right?”

@medoncodoc True, under dx is major challenge. Our data on cardiac amyloid. pmc.ncbi.nlm.nih.gov/articles/PMC99…

📊 Systematic Review of Amyloidosis in India sheds light on important differences vs Western data—highlighting distinct patterns in demographics, disease subtypes, and clinical presentation. 🇮🇳🧬 🧓 Median age of Indian AL amyloidosis patients is ~50 yrs (a decade younger than the West), with strong male predominance (70%). 🛑 Renal involvement is most common. 🔍 AL amyloidosis frequency has tripled over 40 years (13% → 33%) 🦠 Yet, AA amyloidosis (mostly due to tuberculosis) remains the leading cause of renal amyloidosis in India. 💔 Cardiac involvement in 40–50% of patients • Advanced cardiac AL amyloidosis has poor survival (<12 months), despite bortezomib-based regimens • Impact of quadruplet therapy in India still to be seen ❤️‍🔥 In aortic stenosis, ~60% of elderly patients have concomitant ATTR cardiac amyloidosis, influencing disease severity & treatment strategies 🧠 Among patients with paraproteinemic neuropathy: • Most common paraproteinemia: MGUS • Followed by: POEMS syndrome • AL amyloidosis in 4% 🧴 Localized amyloidosis: • Western data → Urothelium most common • Indian data → Skin, head & neck, and ocular regions are predominant 📉 Treatment limitations include underuse of autologous stem cell transplant due to resource constraints. 📚 Most Indian data are retrospective, underscoring the urgent need for prospective studies and improved diagnostics & infrastructure. 🔎 Takeaway: Amyloidosis in India is a distinct clinical entity—early recognition, tailored management, and research are critical. #Amyloidosis #India #mmsm #ALAmyloidosis #AAAmyloidosis #Oncology #RareDiseases #Tuberculosis #CardioOncology @mithunap11 @vishvdeepkhush @pb10_bmt @udaypkulkarni @nihardesai89 @akhilrk1989 @chepsyphilip @HariMenon68 @DrPMPGI @myelomaMD doi.org/10.1016/j.clml…

#ASCO25 Top myeloma abstracts #mmsm Here I provide my list of the 7 most exciting abstracts to watch for in the field of plasma cell disorders Looking for a productive meeting @ASCO 🧵

🧬 🧵ALL in Adults Over 40 | PI Dr. Punit Jain | #ClinicalTrialsDay 1/ 📅 20 May is #ClinicalTrialsDay — a time to recognize how clinical trials transform care and create evidence that saves lives. Promoted by @ACRPDCsince 2014, it celebrates progress — and the people behind it.

@LymphomaMD @Lymphoma_MD @SoniSmithMD @RintuSharmaDM @Charanpreet_14

For a 75 yo with double expresser DLBCL stage IV (leukemic phase), cns not involved but pleura/peritoneal involvement, is there a role for CART in first remission?

I’ve explained this to Dr. Ludwig in person. That happens because once we make criteria, and publish, practice changes. As a result we only see referrals where the referring physician is not sure whether to treat or not, whereas patients they are more confident get labeled as myeloma and treated and we never see those referrals in academic centers For example a patient with 110 FLC ratio at a Hb of 14 and creat of 0.7 and normal MRI is referred. But you don’t see anymore the FLC ratio of 200 or 300 with a Hb of 12 because the clinician is more comfortable calling it myeloma and treating. Or for example an FLC ratio of 110 and BMPC is referred while the FLC ratio of 110 with BMPC of 50% is considered myeloma. Once we publish criteria the population available to me before the criteria are no longer available. These studies are done with patients diagnosed with slim after the 2014 have a patient population with the top end taken off because those the clinicians don’t have a doubt and you end up seeing the borderline ones. And of course the prog rate in the patients we will be less because it’s a selection bias. I see this all the time in referrals. Should I treat patients referred are all the borderline 20% Pc with high FLC ratio. Not the 50% with high FLC ratio. So if take these studies with a grain of salt. It’s important to see if you have a slim cohort diagnosed before 2014 and all consecutive patients seen at an institution(s) to make sure the inception cohort matches ours

@DrGauravNarula @purwarrahul2 @ActImmuno Thank you sir, the @ActImmuno support was incredible

@pb10_bmt @purwarrahul2 @ActImmuno Congratulations Suvir

🌟 Proud Moment! 🌟 We performed the first CAR-T cell therapy in Punjab and the northern Indian region for a patient with refractory B-ALL. This makes us one of the first few institutions in India to offer this level of treatment. @ActImmuno

Honoured to support the incredible team at DMCH in delivering Punjab’s first CAR-T cell therapy for a patient with relapsed leukemia and CNS involvement. Huge thanks to Dr. Suvir Singh (@pb10_bmt) for leading the charge and sharing this milestone. From manufacturing to logistics and clinical guidance - grateful to be part of this milestone. Together, we’re pushing boundaries in Indian cancer treatment. #CARTCellTherapy #ImmunoACT #CancerTreatment #MadeInIndia #BreakthroughTherapy

🧠 AML in Older Adults | Dr. Suvir Singh | 🧵1/ 📅 20 May marks #ClinicalTrialsDay, promoted by @ACRPDC since 2014 to celebrate the people, science, and impact behind clinical research. Today, we spotlight a powerful study on AML in older Indian adults, led by Dr. @pb10_bmt